When you test with Eurofins Discovery’s OncoPanel® and chose our Univariate Genomic Analysis (UGA), you’ll gain data-driven insights on how your test agent’s response correlates with 274,000+ genomic aberrations, amplifications, deletions, coding and non-coding mutations, and gain or loss of function mutations.
Our UGA includes ranking of tumor cell lines by resistance or sensitivity to test agent based on their drug-response, identification of significant genomic features, and cluster analysis of test agent similarity to standards-of-care and reference therapeutics. This information provides key data to help guide patient stratification for efficient clinical trial design, combination therapy approaches to overcome resistance or improve safety, and repositioning efforts to expand or transition from one cancer or tissue type to another.
Client Reports delivered with our OncoPanel UGA also provide data on gene expression changes associated with tumor cell sensitivity or resistance. This analysis includes:
- Summary of top differentially expressed genes related to tumor cell test agent response
- Gene expression changes (differential expression) between cells classified as resistant or sensitive to test agent treatment
- Biological pathways associated with test agent sensitivity or resistance
Genomic analysis can help clinical trials target patients that will derive the most benefit from a treatment:
Figure 1. Genes influencing cancer cell sensitivity or resistance to epigenetic therapeutics GSK343 were discovered using the genomic analysis capabilities of the service. Orthogonal statistical tests identify interesting genetic mutations or copy number alterations(left) and categorize them by effect(right).
Gain patient response insights to benefit:
- Clinical trial design: Identify genomic features that indicate potential resistance mechanisms
- Patient stratification: Reveal genomic features that may influence predisposition to a therapeutic response
- Repurposing or repositioning: Gain insights on new cancer indications for existing drugs, or anticancer indications for drugs from other therapeutic areas based on classification of test agent responses by tumor type
- Competitive benchmarking: Analytics include similarity clustering of test agent responses to 60+ reference drugs and standards-of-care to inform on mechanism-of-action
Genomic analysis of drug response data provided at no additional charge for test agent evaluation across the entire panel of genetically diverse cell lines, all licensed from renowned repositories, or a subset of at least 200 cell line choices from those available. Purchase of UGA is also available for select standards-of-care drugs.
